Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:IMTX

Immatics Q1 2025 Earnings Results & Report

Immatics logo
$7.14 +0.14 (+2.00%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$6.94 -0.20 (-2.79%)
As of 10/15/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immatics beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.35 versus the -$0.39 consensus estimate, while revenue of $20.12 million topped the $14.92 million estimate by $5.20 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
6:00 PM ET

Immatics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Immatics Revenue Results

Actual Revenue
$20.12 million
Expected Revenue
$14.92 million
Beat/Miss
Beat by +$5.20 million
YoY Revenue Growth
N/A

Upcoming Earnings

Immatics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immatics' Q1 2025 Press ReleasePress Release
(8-K)

Immatics Q1 2025 Earnings FAQ

Immatics (NASDAQ:IMTX) reported earnings of -$0.35 per share for Q1 2025, beating the consensus estimate of -$0.39. The report was announced on Tuesday, May 13, 2025.

Immatics reported revenue of $20.12 million for Q1 2025, against a consensus estimate of $14.92 million.

Immatics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immatics on the company's earnings history page.

Immatics Earnings Headlines

Stifel initiates coverage of Immatics NV at buy
October 14 at 12:52 AM  |  msn.comhttps://www.msn.com/en-us/news/other/stifel-initiates-coverage-of-immatics-nv-at-buy/ar-AA2egcj4
Immatics (NASDAQ:IMTX) Sets New 12-Month Low - Here's What Happened
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31102945
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.tc pixel
 |  Brownstone Research (Ad)
Financial Review: Exicure (NASDAQ:XCUR) versus Immatics (NASDAQ:IMTX)
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090807
Immatics and 4 more stocks see action from activist investors
September 4, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/immatics-and-4-more-stocks-see-action-from-activist-investors/ar-AA2bAJ2g
Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=marketbeat.com&utm_medium=referral
See More Immatics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email.

About Immatics

Immatics (NASDAQ:IMTX) (NASDAQ: IMTX) is a biotechnology company focused on developing T cell receptor (TCR)-based therapies for the treatment of cancer. The company identifies cancer targets and designs treatments intended to direct a patient’s immune system toward tumor cells, including solid tumors that may be difficult to address with conventional immunotherapies.

Immatics’ technology platforms support several therapeutic approaches, including TCR-engineered T-cell therapies and TCR-based bispecific molecules that can engage both cancer targets and T cells. Its product pipeline has included candidates directed at targets such as PRAME, a tumor-associated antigen expressed in multiple cancers. The company also uses its target-discovery and validation platforms to identify and evaluate cancer antigens for potential drug development.

Founded in 2000 and headquartered in Tübingen, Germany, Immatics has expanded its operations internationally, including a presence in the United States. The company develops therapies independently and through collaborations with pharmaceutical and biotechnology partners. Immatics is led by Chief Executive Officer Harpreet Singh, who has been associated with the company since its early development.

View Immatics Profile
Earnings Tools